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ORIGINAL ARTICLE
Killing of Escherichia coli by Crohn’s Disease Monocyte-derived
Macrophages and Its Enhancement by Hydroxychloroquine and
Vitamin D
Paul K. Flanagan, MBBS,* Direkrit Chiewchengchol, PhD,†,‡ Helen L. Wright, PhD,†
Steven W. Edwards, PhD,† Abdullah Alswied, MRes,* Jack Satsangi, DPhil,§ Sreedhar Subramanian, MD,jj
Jonathan M. Rhodes, MD,* and Barry J. Campbell, PhD*
Background: Crohn’s disease (CD) is associated with defective innate immunity, including impaired neutrophil chemotaxis, and mucosal invasion by
bacteria, particularly adherent and invasive Escherichia coli that replicate inside macrophage phagolysosomes. We compared CD and healthy control
(HC) macrophages for their abilities to kill E. coli and generate neutrophil chemoattractants and also assessed the effects of hydroxychloroquine (HCQ)
and vitamin D on killing of phagocytosed E. coli.
Methods: Peripheral blood monocyte-derived macrophages from CD and HC were compared for bacterial killing and generation of neutrophil
chemoattractants in response to CD-derived E. coli. Escherichia coli replication was also assessed in the presence and absence of HCQ, alone and with
antibiotics, and vitamin D.
Results: Monocyte-derived macrophages from patients with CD were similar to HC in allowing replication of phagocytosed CD-derived E. coli:
HM605 {CD: N ¼ 10, mean fold replication in 3 hr ¼ 1.08 (95% conﬁdence interval [CI], 0.39–1.78); HC: N ¼ 9, 1.50 (95% CI, 1.02–1.97); P ¼ 0.15}
and also in generation of neutrophil chemoattractants in response to E. coli (mean fold chemotaxis relative to control: CD ¼ 2.55 [95% CI, 2.31–2.80];
HC ¼ 2.65 [95% CI, 2.46–2.85], P ¼ 0.42). HCQ and 1,25 OH2-vitamin D3 both caused dose-dependent inhibition of intramacrophage E. coli
replication 3-hour postinfection; HCQ: 73.9% inhibition (P , 0.001) at 1 mg/mL, accompanied by raised intraphagosomal pH, and 1,25 OH2-vitamin
D3: 80.7% inhibition (P , 0.05) at 80 nM. HCQ had synergistic effects with doxycycline and ciproﬂoxacin.
Conclusions: CD and HC macrophages perform similarly in allowing replication of phagocytosed E. coli and generating neutrophil chemoattractants.
Replication of phagocytosed E. coli was substantially decreased by HCQ and vitamin D. These warrant further therapeutic trials in CD in combination
with relevant antibiotics.
(Inﬂamm Bowel Dis 2015;21:1499–1510)
Key Words: phagolysosomes, chemotaxis, ciproﬂoxacin, doxycycline
T here is growing consensus that Crohn’s disease (CD) resultsfrom an altered relationship between the immune system and
intestinal bacteria.1 Changes in the fecal microbiota, particularly
decreased diversity,2 are also found in animal models of gut
inﬂammation,3 but the mucosa-associated microbiota shows more
speciﬁc changes, even in inactive disease. These include
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decreased colonization by the probiotic Faecalibacterium praus-
nitzii and increase in Escherichia coli.4–6 Similar changes have
been found in the treatment-naive mucosa-associated microbiome
in pediatric CD.7
CD mucosa-associated E. coli commonly adhere to and
invade epithelial cell-lines and are therefore termed adherent–
invasive E. coli (AIEC). Although originally isolated from CD
ileal mucosa, they are also found in the colon.5,7 AIEC taken up
by macrophages are initially destroyed within autophagosomes,8
but some escape this process and replicate within the acidic envi-
ronment of phagolysosomes.9 Phagocytosed AIEC induce granu-
loma formation in vitro10,11 and in animal models.12 This, and the
common presence of E. coli DNA in CD-associated granulomas,11
suggests a possible pathogenic role. AIEC are thought to trans-
locate through microfold cells (M cells) that account for about 5%
of the “dome” epithelium overlying Peyer’s patches in the distal
ileum, and lymphoid follicles in the colon, the sites of the earliest
lesions seen in CD.13,14 CD AIEC commonly express long polar
ﬁmbriae essential for M-cell translocation.6,15
Patients with CD commonly have polymorphisms in genes
(NOD2/CARD15, IRGM, and ATG16L1) linked to pathogen rec-
ognition and autophagy relevant to killing of bacteria within mac-
rophages.16 CD is also associated with defective recruitment of
neutrophils to sites of dermal17 and mucosal18 wounding and
intradermally injected killed E. coli.19 Chemotaxis of CD neutro-
phils is normal when studied ex vivo,20–22 and it has been sug-
gested that delayed chemotaxis in vivo results from defective
macrophage chemokine release.19 The delay in neutrophil chemo-
taxis could then contribute to increased bacterial uptake by
macrophages.
CD peripheral blood monocytes have normal ability to kill
Gram-positive bacteria,23 but there has been no published study of
their killing of Gram-negative bacteria. This is important not only
because of the possible relevance of Gram-negatives such as E. coli
in CD pathogenesis but also because macrophages have distinct
mechanisms for killing of Gram-negative organisms. This includes
interaction with a signaling lymphocyte-activation molecule
involved in activation of NADPH oxidase within phagosomes.24
Proof that intramacrophage E. coli replication may have
a pathogenic role in CD will depend on resolution of the disease
in response to treatments that target these E. coli. Antibiotic ther-
apy has to date been only modestly effective,25 possibly either
because single antibiotics have been used, with multidrug resis-
tance seen in 61.5% of AIEC,26 or because some antibiotics,
particularly penicillins and gentamicin, are unable to kill bacteria
within macrophage vesicles.27
Macrophages are relatively ineffective at killing bacteria in
comparison with neutrophils.28 In Q-fever and Whipple’s disease,
where bacteria, Coxiella burnetii and Tropheryma whipplei,
respectively, replicate inside macrophage phagosomes, addition
of hydroxychloroquine (HCQ) to antibiotics has greatly improved
eradication rates.29–31 Bacteria, including AIEC, that replicate
within macrophage vesicles typically require an acid
environment.9 HCQ is a mild base that is concentrated within
intracellular vesicles thus raising their pH.31
Vitamin D deﬁciency has been implicated in conditions
such as multiple sclerosis and CD that are more common in
countries furthest from the equator.32 Vitamin D is important for
normal function of the innate immune system including autoph-
agy and a controlled trial of vitamin D supplementation in CD,
regardless of their initial vitamin D status, only just failed (P ¼
0.06) to signiﬁcantly reduce relapse.33
Here, we have assessed the ability of CD monocyte-derived
macrophages (MDM) to kill E. coli and to generate a neutrophil
chemotactic response. We then assessed the ability of vitamin D
and HCQ, at clinically achievable concentrations, to enhance
macrophage killing of phagocytosed E. coli.
METHODS
Ethical Considerations
Ethical approval was obtained from the National Research
Ethics Service Committee North-West England (study approval
number 09/H1010/64) to take peripheral venous blood after
informed consent from patients with CD recruited from the Royal
Liverpool University Hospital and healthy controls (HC) recruited
from Liverpool hospital and University staff.
Bacterial Strains and Culture
Two representative CD mucosa-associated AIEC isolates
were studied; HM605, a colonic isolate,5 and LF82, an ileal isolate.4
Both isolates replicate within phagolysosomes of murine and human
MDM.9,27,34 Laboratory strain E. coliK12 (ATCC 29425; Manassas,
VA) and Staphylococcus aureus Oxford stain (NCTC 6571;
Public Health England; Porton Down, United Kingdom) were also
tested. Isolates were grown overnight on Luria-Bertani (LB) agar at
378C in air, washed 3 times in sterile phosphate-buffered saline pH
7.3 (Life Technologies; Paisley, United Kingdom), and resuspended
to an optical density (OD550 nm) equivalent to 109 bacteria per
milliliter.
Murine Macrophage Cell-line Culture
J774A.1 murine macrophages (91051511) obtained from
the European Collection of Cell Cultures (Porton Down; United
Kingdom) were cultured at 378C in RPMI medium supplemented
with 10% vol/vol fetal bovine serum, 2 mM glutamine, 50 U/mL
penicillin, and 50 mg/mL streptomycin, in a humidiﬁed atmo-
sphere of 5% CO2 per 95% air. Macrophages were passaged by
scraping twice weekly, up to passage 19.
Isolation of Human Peripheral Blood MDM
and Neutrophils
Peripheral venous blood was taken after informed consent
from 10 patients with CD recruited from the Royal Liverpool
University Hospital and 10 HC recruited from Liverpool hospital
and University staff. Tables, Supplemental Digital Content 1,
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http://links.lww.com/IBD/A836, for inclusion/exclusion criteria
(see Table 1, Supplemental Digital Content 1, http://links.lww.
com/IBD/A836), baseline characteristics (equivalent apart from
higher hsCRP in CD) (see Table 2, Supplemental Digital Content
1, http://links.lww.com/IBD/A836), and patient characteristics
(see Table 3, Supplemental Digital Content 1, http://links.lww.
com/IBD/A836). Five patients with CD had active disease
(Harvey–Bradshaw Index . 4). None were receiving immuno-
suppressants, corticosteroids, or anti-tumor necrosis factor (TNF)
therapy, and none had features of sepsis (median hsCRP ¼ 5.9
mg/L; range, 1.04–18.3 mg/L) at the time of sampling. Blood
(50 mL) was immediately heparinized using unfractionated hep-
arin sodium 5 U/mL (Wockhardt UK Ltd, Wrexham; Wales),
mixed 1:1 with phosphate-buffered saline, layered over Lympho-
prep (Alere; Stockport, United Kingdom), and centrifuged at 800g
for 20 minutes at room temperature. Mononuclear cells were aspi-
rated, washed, resuspended in RPMI supplemented with 20 mM
HEPES pH 7.4, 100 U/mL penicillin, and 100 mg/mL streptomy-
cin, adjusted to 5 · 106 cells per milliliter and seeded into 100 mm
Nunc culture dishes (VWR; Lutterworth, United Kingdom). After
2-hour incubation at 378C, nonadherent cells were removed by
washing and adherent monocytes differentiated into macrophages
over 5 days.19
Neutrophils were isolated from heparinized venous blood
using Polymorphprep (Alere) according to manufacturer’s instruc-
tions and, after removal of red cells by hypotonic lysis, resus-
pended in RPMI with 20 mM HEPES pH 7.4, 0.5% vol/vol
bovine serum albumin, 2 mM CaCl2, and 2 mM MgCl2.
Intramacrophage Bacterial Killing
Ability of human MDM and J774A.1 macrophages to kill
phagocytosed bacteria was assessed by a gentamicin protection
assay.27 Macrophage monolayers were inoculated with bacteria at
a multiplicity of infection of 25 (for MDM) or 10 (J774.A1). After
2-hour infection, macrophages were washed thrice with sterile
phosphate-buffered saline and incubated for 1 hour in RPMI con-
taining 10% vol/vol fetal bovine serum, 2 mM glutamine (for
J774.A1) or in X-Vivo 15 (for MDMs), and 20 mg/mL gentamicin
to kill adherent, noninternalized bacteria. Macrophages were
washed and lysed with 1% vol/vol Triton X-100 for 5 minutes
to release internalized bacteria. Bacteria colony-forming units
were counted after overnight culture on LB agar. Parallel plates
were cultured for a further 3 hours after 1-hour incubation with
gentamicin (6 hr in total), again followed by lysis and overnight
colony-forming units counting. Data were expressed as fold
change of recovered intramacrophage bacteria at 6 hours relative
to 3 hours.
Effects of HCQ, with and Without Antibiotics,
and Vitamin D on Intramacrophage Survival
of CD AIEC
Doxycycline and ciproﬂoxacin were tested at Cmax (peak
serum concentration achieved with standard oral dosing) and 10%
Cmax, based on published data.
35,36 HCQ concentrations were
based on published steady state concentrations.37 Concentrations
of 1,25 OH2-vitamin D3 were those deﬁned as deﬁcient in human
serum (,20 nM)32,38 and that required for optimal immune cell
function (.80 nM).32,39
Cytokine Enzyme-linked
Immunosorbent Assays
Interleukin 6 (IL-6), IL-8, and TNF-a were quantiﬁed by
enzyme-linked immunosorbent assay as per manufacturer’s in-
structions (R&D systems; Abingdon, United Kingdom; IL-6,
D6050; IL-8, D800C; TNF-a, DTA00C). Murine IL-6 and
TNF-a released by J774A.1 macrophages were also deter-
mined by enzyme-linked immunosorbent assay (R&D systems;
IL-6, M6000B; TNF-a, SMTA00B). OD450 nm was measured
using a Sunrise microplate reader (Tecan; Theale, United
Kingdom).
Neutrophil Chemotaxis Assay
Neutrophil chemotaxis was quantiﬁed using a CytoSelect
96-Well Cell Migration Assay, 3 mm pore diameter (Cambridge
Bioscience; Cambridge, United Kingdom) as per manufacturer’s
instructions. Chemoattractant in the lower chamber was X-Vivo
15 medium from 105 MDM either uninfected or infected for 6
hours with E. coli HM605 or K12 (multiplicity of infection of 25).
CyQuantGR ﬂuorescence was measured using an F200 micro-
plate reader (Tecan); excitation l 485 nm, emission l 535 nm.
Effect of HCQ on Macrophage
Intraphagolysosome pH
J774A.1 macrophages cultured in 35 mm CELLview dishes
(Greiner Bio-One; Stonehouse, United Kingdom) were washed
and incubated in phenol red-free RPMI containing 10 mg/mL
pHrodo-conjugated E. coli bioparticles and HCQ (0–10 mg/mL)
for 3 hours at 378C. Imaging was by a Zeiss LSM-510 meta-laser
confocal microscope with atmosphere- and temperature-
controlled stage (Carl Zeiss AG, Oberkochen, Germany). Ten
random high-powered ﬁelds were imaged for each treatment, pro-
cessed using LSM-5 software (Zeiss AG), and ﬂuorescence inten-
sity analyzed with AQM-6 (Kinetic Imaging; Nottingham, United
Kingdom). A pH-calibration curve was constructed by incubation
of pHrodo bioparticle-loaded macrophages with buffers (pH 4–7)
containing ionophores nigericin (10 mM) and vanilomycin
(10 mM) plus the vacuolar H+-ATPase inhibitor baﬁlomycin
(0.1 mM).40 NH4Cl (2 mM) was used as an intraphagolysosome
alkalinization control.
Inﬂuence of Intracellular Iron Availability on
the Action of HCQ
To determine whether the antibacterial actions of HCQ
were mediated through pH-mediated restriction of intramacro-
phage iron, macrophages were pretreated with either 10 mM ferric
citrate, which exhibits pH-dependent solubility and release of free
ferric iron, or 10 mM ferric nitrilotriacetic acid (FeNTA), which
releases free ferric iron irrespective of pH.41
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Genomic Analysis for CD-associated
Polymorphisms in NOD2/CARD15, ATG16L1,
and IRGM
Genomic DNA was extracted using a Nucleon BACC3 kit
(Gen-Probe; Livingston, United Kingdom) from EDTA-treated
peripheral venous blood taken from patients with CD and HC in
whom macrophage function studies were also performed. DNA
yield was determined using PicoGreen (Life Technologies), and
samples normalized to 10 ng/mL. Single nucleotide poly-
morphisms were analyzed by TaqMan quantitative polymerase
chain reaction for NOD2/CARD15 (rs2066844, rs2066845, and
rs2066847), ATG16L1 (rs2241880), and IRGM (rs13361189).42
Cytotoxicity Assay
Macrophage viability was assessed by measuring release of
intracellular adenylate kinase into supernatants over 6 hours after drug
treatments and/or bacterial infection using the ToxiLight bioassay kit
as per manufacturer’s instructions (Lonza; Slough, United Kingdom).
Luminescence was measured on a Tecan F200 microplate reader.
Statistical Analysis
N indicates number of patients or independent experiments
performed with cells seeded in triplicate for each experiment. Sample
groups were assessed for normality and equality of variances.
Comparison of CD patient data versus HC was by Mann–Whitney
U test. Dose–response experiments were analyzed using Cuzick’s
test for trend, followed, where signiﬁcant, by Dunnett’s test. Other
multiple treatment experiments were analyzed using one-way analy-
sis of variance followed by selected pair-wise comparison of treat-
ment means (StatsDirect; Sale, United Kingdom). Differences were
considered signiﬁcant when two-tailed, P , 0.05.
RESULTS
MDM from HC and Patients with CD Have
Equivalent Ability to Kill Intracellular Bacteria
Neither CD nor HC peripheral blood MDM were very
effective at killing E. coli. CD MDM allowed net replication of
phagocytosed CD-derived E. coli HM605 (CD: N ¼ 10 patients,
mean fold replication over 3 hours ¼ 1.08 [95% CI, 0.39–1.78])
as did HC MDM (N ¼ 9, 1.50 [95% CI, 1.02–1.97]; P ¼ 0.15;
Mann–Whitney U test). Similar results were obtained for replica-
tion of phagocytosed E. coli K12 (CD: N ¼ 10, mean fold rep-
lication over 3 hours ¼ 0.54 [95% CI, 0.24–0.84]; HC: N ¼ 10,
0.86 [95% CI, 0.47–1.26]; P ¼ 0.14) and also for phagocytosed S.
aureus (CD: N ¼ 10, mean fold replication ¼ 0.37 [95% CI,
0.18–0.55]; HC: N ¼ 10, 0.48 [95% CI, 0.39–0.57]; P ¼ 0.09)
(Fig. 1). There was a nonsigniﬁcant trend toward increased intra-
macrophage replication of HM605 among patients with CD with
active disease (mean fold replication ¼ 1.74 [95% CI, 0.67–2.81])
compared with those with inactive disease (mean ¼ 0.43 [95% CI,
0.0–0.87], P ¼ 0.10), but replication of HM605 in patients with
active disease was similar to that seen in HC (Fig. 2). No
correlation was seen between the total number of affected
NOD2/CARD15 and ATG16L1 alleles and ability to kill intrama-
crophage HM605, but none of the patients with CD studied were
homozygous for affected NOD2/CARD15 or IRGM alleles, and
only 1 was homozygous for affected ATG16L1 (Fig. 2).
MDM from HC and Patients with CD Have
Equivalent Ability to Generate Neutrophil
Chemoattractants in Response to E. coli
HC and CD E. coli–infected MDM were more able to
induce neutrophil chemotaxis than uninfected MDM but with
no signiﬁcant difference between CD (N ¼ 10 patients) and HC
(N ¼ 7): HM605 (CD: mean fold change in neutrophil chemotaxis
¼ 2.55 [95% CI, 2.31–2.80]; HC: 2.65 [95% CI, 2.46–2.85], P ¼
0.42 Mann–Whitney U test); K12 (CD: 2.20 [95% CI, 1.78–2.63];
HC: 2.23 [95% CI, 1.86–2.60], P ¼ 0.89) (Fig. 3). No signiﬁcant
difference was seen in the chemotactic response generated by
MDM derived from patients with active CD compared with those
with inactive disease (P ¼ 0.60) (see Table 3, Supplemental Dig-
ital Content 1, http://links.lww.com/IBD/A836).
Production of cytokines by human MDM in response to
HM605 infection was also equivalent between CD (N ¼ 10 pa-
tients) and HC (N ¼ 7); TNF-a (CD: mean ¼ 1915.3 pg/mL [95%
CI, 1711.6–2119.0]; HC: mean ¼ 1823.2 pg/mL [95% CI,
1590.6–2055.7], P ¼ 0.27); IL-6 (CD: mean ¼ 1720.1 pg/mL
[95% CI, 1178.0–2262.3]; HC: mean ¼ 1209.9 pg/mL [95%
CI, 710.6–1709.1], P ¼ 0.23); IL-8 (CD: mean ¼ 6643.9 pg/
mL [95% CI, 5065.5–8222.4]; HC: mean ¼ 6639.0 pg/mL
[95% CI, 4064.6–9213.4], P ¼ 0.89).
HCQ Enhances Intramacrophage Killing of
AIEC in Murine and Human Macrophages
HCQ induced a dose-dependent enhancement of intracellular
killing of HM605 by J774A.1 macrophages (P , 0.001, Cuzick’s
test for trend). Net replication of E. coli (mean fold replication over
3 hr: 3.59 6 0.35) occurred in the untreated control, but, at con-
centrations of HCQ at $2 mg/mL, net killing of E. coli occurred
(Fig. 4A). Similar results were obtained with nonhydroxylated
chloroquine (see Fig, Supplemental Digital Content 2, http://links.
lww.com/IBD/A837). HCQ also induced dose-dependent enhance-
ment of intracellular killing of HM605 in human MDM (P ,
0.001, Cuzick’s test) (Fig. 4B). It should be noted that HCQ, up
to 10 mg/mL, showed no signiﬁcant direct effect on growth of
HM605 in broth over 7 hours monitored at OD600 nm (Fig. 4C)
and by colony-forming units on LB agar (see Fig, Supplemental
Digital Content 3, http://links.lww.com/IBD/A838).
HCQ Raises Phagolysosomal pH and Alters
Intracellular Iron Metabolism
Addition of HCQ to HM605-infected J774A.1 macro-
phages caused a dose-dependent increase in phagolysosomal pH
(N ¼ 6, P, 0.005, Cuzick’s test). From a baseline of 5.216 0.31
(mean 6 SEM), pH increased stepwise to 5.56 6 0.36 at HCQ 5
mg/mL and 7.25 6 0.47 at 10 mg/mL (Fig. 5).
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Cotreatment with the iron substrates, ferric citrate (allow-
ing pH-dependent release of ferric iron) and FeNTA (allowing
release of ferric iron irrespective of pH), only partially reversed
the effect of HCQ, with a signiﬁcant but partial effect seen only
at 5 to 10 mg/mL HCQ (Fig. 5).
A modest trend toward increased cathepsin G (P ¼ 0.03,
Cuzick’s test) and macrophage elastase MMP12 (P ¼ 0.04) activ-
ity was seen in whole cell lysates of HM605-infected macro-
phages treated with HCQ (see Data, Supplemental Digital
Content 4, http://links.lww.com/IBD/A839).
FIGURE 2. Presence of NOD2/CARD15 and ATG16L1 variants were not associated with altered ability to kill intramacrophage CD-derived E. coli
HM605. Patient NOD2/CARD15 and ATG16L1 status reported as number of disease associated alleles. A, Killing of intramacrophage HM605 was
unaffected by the total number of variant NOD2 and ATG16L1 alleles (possible range, 0–4: zero affected, N ¼ 7; one affected, N ¼ 10; two affected,
N ¼ 2) (zero versus one affected allele, P ¼ 0.18; zero versus two affected alleles, P ¼ 0.65; one versus two affected alleles, P ¼ 0.20, analysis of
variance). B, Effect of disease activity on killing of E. coli HM605 (P ¼ 0.10, Mann–Whitney U test).
FIGURE 1. MDM isolated from patients with CD and HC possess similar ability to kill phagocytosed bacteria. No signiﬁcant differences were seen
between CD and HC in the killing of any of the bacteria tested; (A) AIEC HM605, (B) E. coli K12, and (C) S. aureus. Each point represents individual
patient mean of triplicate samples, horizontal bar indicates overall mean.
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HCQ decreased intracellular respiratory burst as as-
sessed by ﬂow cytometric measurement of dihydrorhodamine
ﬂuorescence (P , 0.05, Cuzick’s test) but did not affect
total respiratory burst as assessed by lucigenin-mediated
luminescence (P ¼ 0.73, Cuzick’s test); (see Data, Supple-
mental Digital Content 5, http://links.lww.com/IBD/A840).
HCQ neither alter production of TNF-a (P ¼ 0.31, Cuzick’s
test) nor IL-6 (P ¼ 0.79) from HM605-infected J774A.1
murine macrophages (Fig, Supplemental Digital Content 6,
http://links.lww.com/IBD/A841).
HCQ Enhances the Antimicrobial Effect of
Doxycycline and Ciproﬂoxacin Against AIEC
Replicating Within Macrophages
Doxycycline at 10% Cmax was ineffective at killing intra-
macrophage HM605 (89.01% 6 8.57%, mean% 6 SEM% sur-
vival relative to control, P ¼ 0.08) and only achieved modest
decreases in viable bacteria at Cmax (75.5% 6 6.72%, P ,
0.01). However, at both 10% Cmax (48.9% 6 5.36%, P ,
0.001) and Cmax (34.49 6 4.71, P , 0.001), cotreatment with
HCQ plus doxycycline led to signiﬁcant enhancement of bacterial
killing relative to control and was also signiﬁcantly more effective
than antibiotic monotherapy (P , 0.001 at both 10% Cmax and
Cmax; N ¼ 6). (Fig. 6).
Ciproﬂoxacin effectively killed intramacrophage HM605
at 10% Cmax (4.95% 6 0.92%, mean% 6 SEM% survival
relative to control, P , 0.001) and led to near complete killing
at Cmax (0.2% 6 0.0%, P , 0.001). Combination of HCQ with
ciproﬂoxacin was more effective than antibiotic monotherapy
at 10% Cmax (2.8% 6 0.82%, P , 0.05), but at Cmax, no
additional effect was seen (0.3% 6 0.1%, P ¼ 0.86) (N ¼
3). Similar results were obtained for killing of intramacrophage
ileal CD AIEC LF82 (see Fig, Supplemental Digital Content 7,
http://links.lww.com/IBD/A842).
FIGURE 3. E. coli-infected MDM from patients with CD and HC have equivalent ability to generate neutrophil chemoattractants. A, MDM-induced
neutrophil chemotaxis was equivalent between CD (N ¼ 10) and HC (N ¼ 9) whether uninfected or infected with E. coli (either AIEC HM605 or
K12). Infected macrophages induced greater neutrophil chemotaxis than uninfected controls (P, 0.001; analysis of variance). MDM production of
(B) IL-8, (C) IL-6, and (D) TNF-a in response to HM605 infection were also equivalent between CD (N ¼ 10) and HC (N ¼ 7). All assays performed in
triplicate. P values by Mann–Whitney U test.
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Vitamin D Enhances Killing of
Intramacrophage AIEC
Intramacrophage HM605 survival was decreased by treat-
ment with 1,25 OH2-vitamin D3 in a dose-dependent manner; in
human MDM (P ¼ 0.012, Cuzick’s test) and in J774A.1 macro-
phages (P , 0.001); (Fig. 7). Cotreatment with 1,25 OH2-vitamin
D3, modestly increased intracellular respiratory burst in J774A.1
macrophages relative to vehicle-treated control (N ¼ 5, P ¼
0.002, Cuzick’s test). No effect was seen on total (intracellular
plus extracellular) respiratory burst (see Data, Supplemental Dig-
ital Content 5, http://links.lww.com/IBD/A840). No macrophage
cytotoxicity was seen as assessed by released adenylate kinase in
response to any of the drugs tested or vitamin D.
DISCUSSION
Here, we show that MDM from healthy individuals are
ineffective at killing CD mucosally derived AIEC, but that CD
MDM are similarly ineffective. Moreover, the CD MDM show no
defect in generation of neutrophil chemoattractants in response to
E. coli. Since E. coli replicating within macrophage phagolyso-
somes represent a plausible therapeutic target in CD, and are likely
to be relatively resistant to antibiotic therapy, we investigated the
effects of HCQ and 1,25 OH2-vitamin D3 on killing of CD E. coli
by macrophages. Both HCQ and 1,25 OH2-vitamin D3 are shown
to greatly enhance the ability of macrophages to kill phagocytosed
E. coli. The effect of HCQ is synergistic with antibiotics, suggest-
ing a plausible new approach to therapy.
Defective neutrophil chemotaxis has been consistently
reported in patients with CD. Neutrophils are usually plentiful
in CD tissue sections, but it has been suggested that a delayed
neutrophil response to an initial bacterial attack may result in
bacteria being taken up by macrophages before the neutrophils
arrive.18 These macrophages, being much less effective than neu-
trophils at killing phagocytosed bacteria, may then become chron-
ically infected, resulting in granuloma formation. It has been
suggested that the decreased in vivo neutrophil chemotaxis seen
in CD may be due to a defective macrophage chemokine response
to bacterial triggers.19 Studies have shown defective secretion of
IL-8 by CD MDM in response to the NOD2 ligand muramyl
dipeptide18 and into CD blister ﬂuid.43 In the latter study, blister
ﬂuid concentrations of IL-8, but not those of TNF-a or other
cytokines, correlated with decreased chemotaxis. However, sub-
sequent studies of CD MDM have shown decreased secretion of
TNF-a and other cytokines but not IL-8.19,44 Here, CD peripheral
FIGURE 4. HCQ enhances intramacrophage killing of AIEC. HCQ treatment causes a dose-dependent decrease in survival of intramacrophage AIEC HM605
in (A) J774A.1 murine macrophages (N ¼ 3, Cuzick’s test for trend P , 0.001) and (B) healthy human MDM (N ¼ 5, Cuzick’s test; P, 0.001). ***P, 0.001,
Dunnett’s test versus control. C, HCQ did not have a direct bactericidal action as observed by growth in broth, measured at OD600 nm (N ¼ 3).
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blood MDM behaved similarly to those from HC in their ability to
generate neutrophil chemoattractants in response to E. coli; their
E. coli-induced secretion of IL-8, TNF-a, and other cytokines was
also similar. A defective macrophage cytokine response has pre-
viously been reported in individuals who are homozygous or
compound heterozygous for altered NOD2/CARD15 alleles,18,44,45
but this genotype is only present in around 8% of CD and was not
present in any patients in our study. The mechanism underlying
the defective neutrophil chemotaxis seen in vivo in the majority of
patients with CD is therefore still unclear, but the presence of
circulating chemotaxis inhibitors remains a possibility.46–48
Peripheral blood MDM from patients with CD have
previously been shown to be normal in their ability to kill
phagocytosed S. aureus.23 Given the different mechanisms
involved in killing of Gram-negative organisms by macrophages,
it was important also to assess the ability of CD macrophages in
killing AIEC. It is shown here that even healthy macrophages are
ineffective at killing phagocytosed E. coli including AIEC but that
CD macrophages are no worse. It has recently been shown that
MDM from patients with CD, homozygous for the ATG16L1 risk
allele show impaired killing of phagocytosed AIEC when studied
in the presence of phorbol ester to mimic inﬂammatory condi-
tions.49 Only 1 of the patients in this study was homozygous for
the ATG16L1 risk allele.
The mechanisms by which microbes evade intramacro-
phage killing include resistance to pH changes, prevention of
phagosomal maturation, escape into the cytosol, and resistance to
reactive oxygen species.50,51 This is typiﬁed by C. burnetii, the
agent of Q-fever, which is adapted to survive at the acidic pH
within macrophage phagolysosomes.52,53 Although CD AIEC iso-
lates, such as LF82, are rapidly attacked through the autophago-
cytic pathway,8 some can escape autophagy and then survive and,
FIGURE 5. HCQ leads to alkalinization of macrophage phagolysosomes, and its effects on killing of phagocytosed E. coli are only partly reversed by iron
supplementation. A, HCQ increased phagolysosomal pH in AIEC HM605-infected J774A.1 macrophages as assessed by confocal microscopy (n ¼ 6,
Cuzick’s test for trend P , 0.005). **P , 0.01 Dunnett’s test versus control. B, Representative standard curve of mean confocal-acquired ﬂuorescence of
pHrodo E. coli bioparticle-loaded macrophages with phagolysosomes equalized in calibration buffers at pH 4 to pH 7 (n ¼ 3). C, Confocal images
illustrating increased phagolysosomal pH with 10 mg/mL HCQ (HCQ10) as indicated by decreased pHrodo ﬂuorescence compared with untreated
control (left panel). Onset of the change in pH occurs within 30 minutes (right panel). D, Iron supplementation only partially antagonizes the effect of
HCQ on intracellular survival of AIEC HM605 in J774A.1 macrophages (N ¼ 3; *P , 0.05, **P , 0.01, ***P , 0.001 analysis of variance).
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like C. burnetii, replicate within mature phagolysosomes, which
provide them with the acidic pH necessary for their replication.9
The survival of C. burnetii within macrophages is substantially
decreased in vitro by HCQ treatment and this translated into
clinical response in a randomized trial.54 Similar effects have been
seen for HCQ against T. whipplei, the causative organism of
Whipple’s disease and a combination of doxycycline and HCQ
is now recommended as ﬁrst-line therapy.55 This study shows
a marked effect of HCQ on survival of phagocytosed AIEC within
macrophages, similar to that previously shown for chloroquine9
and probably mediated largely by increased intravacuolar pH.
We have shown here that HCQ, at concentrations that should
be achievable in vivo, has a marked synergistic effect with
antibiotics, such as ciproﬂoxacin and doxycycline that are effective
against intracellular E. coli. HCQ has not proved effective when
used, mainly on the basis of its anti-inﬂammatory effects, as a single
agent in CD,56 although it has been successfully used in the treatment
of chronic granulomatous disease, an inherited condition associated
with defective neutrophil function, impaired NADPH oxidase free-
radical production and granulomatous colitis that mimics CD.57 Erad-
ication of E. coli replicating within tissue macrophages, in analogy
with the causative organisms of Whipple’s disease and Q-fever, will
almost certainly require that HCQ is combined with appropriate anti-
biotics. This approach has a proven safety record even with long-
term treatment.58
In view of the associations between CD and polymorphisms
in genes such as NOD2/CARD15, ATG16L1, and IGRM, all of
which impact on autophagy, it has been suggested that stimulation
of autophagy would be a plausible therapeutic strategy.8 It might
therefore seem counterintuitive to consider a drug such as HCQ
FIGURE 6. HCQ enhances antibiotic efﬁcacy against intramacrophage AIEC. Combination therapy (antibiotic plus HCQ, 1 mg/mL) was more
effective at killing AIEC HM605 within J774.A1 macrophages than antibiotic monotherapy at (A) 10% Cmax doxycycline and (B) Cmax doxycyline [2
mg/mL]; N ¼ 6. Likewise, for (C) 10% Cmax ciproﬂoxacin. D, No additional beneﬁt was seen with ciproﬂoxacin at Cmax [4 mg/mL]; N ¼ 3. *P , 0.05,
***P , 0.001, ***P , 0.001; analysis of variance.
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that, like other quinolone antimalarials, inhibits the late stages of
autophagy, particularly fusion of autophagosomes with lyso-
somes.59 This effect is dose-dependent, however, and it has been
reported that chloroquine may even enhance fusion at lower con-
centrations.60 In support of this, it has been shown to inhibit intra-
macrophage replication of Mycobacterium tuberculosis and to
enhance the antituberculosis protectiveness of both isoniazid and
25 OH-vitamin D3.
61 Moreover CD-derived AIEC can replicate
within phagolysosomes, having escaped autophagy,9 whereas ra-
pamycin, which stimulates autophagy, becomes ineffective once
intramacrophage replication of AIEC has become established.8
Vitamin D has been shown to be important to autophagy
and other aspects of the innate immune response.32,39,62 We have
shown here that vitamin D, also at concentrations readily achiev-
able with oral supplementation, substantially enhances the ability
of human MDM to kill phagocytosed E. coli. There is clear jus-
tiﬁcation for further studies of vitamin D supplementation in CD.
It can currently still be argued that the increase in
mucosally associated E. coli commonly found in CD may be
a secondary phenomenon. Proof of the direct involvement of
E. coli in CD pathogenesis now depends on showing that a therapy
targeted against E. coli replicating within macrophages can induce
remission in CD. A controlled trial of combination ciproﬂoxacin/
doxycycline/HCQ therapy in active CD has therefore been com-
menced (ClinicalTrials.gov NCT01783106).
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